Rachel D. Crouch

Rachel D. Crouch

Auto-generated profile, based on publicly available information

Rachel D. Crouch

Department of Pharmacy and Pharmaceutical Sciences, Lipscomb University College of Pharmacy, Nashville, TN, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

15 March 2023 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
PDF file
JBJ. Paige Barnes
J. Paige Barnes
SYShaoyun M. Yang
Shaoyun M. Yang
TTTaylor S. Thompson
Taylor S. Thompson
CGCaithlyne M. Guevarra
Caithlyne M. Guevarra
SPShaniya S. Pleasant
Shaniya S. Pleasant
RCRachel D. Crouch
Rachel D. Crouch
The anti-hypertensive agent hydralazine is a time-dependent inhibitor of the cytosolic drug metabolizing enzyme aldehyde oxidase (AO). Glutathione (GSH) was found to suppress the inhibition of AO by hydralazine in multiple enzyme sources (human liver and kidney cytosol, human liver S9, rat liver S9, and recombinant human AO) and with different AO substrates (zoniporide, O6-benzylguanine, and dantrolene). Hydralazine-induced AO inactivation was unaffected when GSH was added to the incubation mixture after pre-incubation of hydralazine with AO (rather than during the pre-incubation), suggesting that GSH traps a hydralazine reactive intermediate prior to enzyme inactivation. Consistent with previous reports of 1-phthalazylmercapturic acid formation when hydralazine was incubated with N-acetylcysteine, we detected a metabolite producing an MS/MS spectrum consistent with a 1-phthalazyl-GSH conjugate. O6-Benzylguanine, an AO substrate, did not protect against hydralazine-induced AO inactivation, implying that hydralazine does not compete with O6-benzylguanine for binding to the AO active site. Catalase also failed to protect AO from hydralazine-induced inactivation, suggesting that hydrogen peroxide is not involved. However, an allosteric AO inhibitor (thioridazine) offered some protection, indicating a catalytic role for AO in the bioactivation of hydralazine. AO inhibition by phthalazine (a substrate and inhibitor of AO and a metabolite of hydralazine) was unaffected by the presence of GSH. GSH also prevented hydralazine from inhibiting the nitro-reduction of dantrolene by AO. Furthermore, the GSH-hydralazine combination stimulated dantrolene reduction. Phthalazine inhibited only oxidation reactions, not reduction of dantrolene. Together these results support the hypothesis that hydralazine is converted to a reactive intermediate that inactivates AO. Significance Statement These studies suggest that a reactive intermediate of hydralazine plays a primary role in the mechanism of aldehyde oxidase (AO) inactivation. Inactivation was attenuated by glutathione and unaffected by catalase. Phthalazine (hydralazine metabolite) inhibited AO regardless of the presence of glutathione; however, phthalazine inhibited only oxidation reactions, while hydralazine inhibited both oxidation and reduction reactions. This report advances our mechanistic understanding of hydralazine as an AO inhibitor and provides information to facilitate appropriate use of hydralazine when probing AO metabolism.

3 July 2022 in Drug Metabolism Reviews
Verified
Journal Article
Open access
CKCyrus Khojasteh
Cyrus Khojasteh
UAUpendra A. Argikar
Upendra A. Argikar
SCSungjoon Cho
Sungjoon Cho
RCRachel Crouch
Rachel Crouch
CHCarley J. S. Heck
Carley J. S. Heck
KJKlarissa Jackson
Klarissa Jackson
Biotransformation field is constantly evolving with new molecular structures and discoveries of metabolic pathways that impact efficacy and safety. Recent review by Kramlinger et al (2022) nicely captures the future (and the past) of highly impactful science of biotransformation (see the first article). Based on the selected articles, this review was categorized into three sections: (1) new modalities biotransformation, (2) drug discovery biotransformation, and (3) drug development biotransformation (Table 1).

3 July 2022 in Drug Metabolism Reviews
Verified
Journal Article
Open access
KJKlarissa Jackson
Klarissa Jackson
UAUpendra A. Argikar
Upendra A. Argikar
SCSungjoon Cho
Sungjoon Cho
RCRachel D. Crouch
Rachel D. Crouch
JDJames Driscoll
James Driscoll
CKCyrus Khojasteh
Cyrus Khojasteh
This year’s review on bioactivation and reactivity began as a part of the annual review on biotransformation and bioactivation led by Cyrus Khojasteh (see references). Increased contributions from experts in the field led to the development of a stand alone edition for the first time this year focused specifically on bioactivation and reactivity. Our objective for this review is to highlight and share articles which we deem influential and significant regarding the development of covalent inhibitors, mechanisms of reactive metabolite formation, enzyme inactivation, and drug safety. Based on the selected articles, we created two sections: (1) reactivity and enzyme inactivation, and (2) bioactivation mechanisms and safety (Table 1). Several biotransformation experts have contributed to this effort from academic and industry settings.

31 August 2022
Verified
Book Chapter
Closed access
PDF file
KCKevin A. Clauson
Kevin A. Clauson
RCRachel D. Crouch
Rachel D. Crouch
EBElizabeth A. Breeden
Elizabeth A. Breeden
NSNicole Salata
Nicole Salata

17 July 2021
Verified
Book Chapter
Open access
PDF file
RCRachel D. Crouch
Rachel D. Crouch
JBJessica Beers
Jessica Beers
KJKlarissa Jackson
Klarissa Jackson
Often it may be convenient and efficient to address multiple research questions with a single experiment. In many instances, however, the best approach is to design the experiment to address one question at a time. The design of enzyme mapping experiments is discussed in this chapter, focusing on considerations pertinent to the study of aldehyde oxidase (AO) vs. cytochrome P450 metabolism. Specifically, a case is presented in which reduced glutathione (GSH) was included in an experiment with human liver S9 fraction to trap reactive metabolites generated from cytochrome P450-mediated metabolism of lapatinib and its O-dealkylated metabolite, M1 (question 1). The AO inhibitor hydralazine was included in this experiment to investigate the involvement of AO-mediated metabolism of M1 (question 2). The presence of GSH was found to interfere with the inhibitory activity of hydralazine. Consideration of the time-dependent nature of hydralazine inhibitory activity toward AO when designing this experiment could have predicted the potential for GSH to interfere with hydralazine. This case underscores the importance of clearly identifying the research question, tailoring the experimental protocol to answer that question, and then meticulously considering how the experimental conditions could influence the results, particularly if attempting to address multiple questions with a single experiment.